Key Financial Performance (Consolidated)

Q2FY27 Performance

  • Net Revenue from Operations: ₹1,810.4 Cr, up 36.5% YoY from ₹1,326.2 Cr in Q2FY26
  • EBITDA: ₹195.9 Cr, up 68.4% YoY from ₹116.3 Cr in Q2FY26
  • EBITDA Margin: 10.8% vs 8.7% in Q2FY26
  • PAT: ₹119.8 Cr, up 80.1% YoY from ₹66.5 Cr in Q2FY26
  • PAT Margin: 6.6% vs 5.0% in Q2FY26
  • EPS: ₹33.78 vs ₹18.75 in Q2FY26

H1FY27 Performance

  • Net Revenue from Operations: ₹3,592.3 Cr, up 37.9% YoY from ₹2,604.1 Cr in H1FY26
  • EBITDA: ₹448.4 Cr, up 78.4% YoY from ₹251.4 Cr in H1FY26
  • EBITDA Margin: 12.4% vs 9.6% in H1FY26
  • PAT: ₹285.7 Cr, up 95.7% YoY from ₹146.0 Cr in H1FY26
  • PAT Margin: 7.9% vs 1.2% in H1FY26
  • EPS: ₹80.58 vs ₹41.17 in H1FY26

Notably, H1FY27 PAT of ₹285.7 Cr has already surpassed the full-year FY26 PAT of ₹267.4 Cr.

Segment Performance Highlights

Volume Growth (YoY)

Q2FY27:

  • Performance Surfactant: Mid-teens growth
  • Specialty Care: Flat
  • India: Mid-teens growth
  • AMET: Mid-teens growth
  • ROW: High single-digit decline

H1FY27:

  • Performance Surfactant: High single-digit growth
  • Specialty Care: Low single-digit growth
  • India: Mid-teens growth
  • AMET: Mid single-digit growth
  • ROW: Flat

Key Developments

1. Consolidated volumes grew in high single digits, led by mid-teens growth in Performance Surfactants segment

2. EBITDA/MT improved to ₹26,920/MT driven by volume growth, disciplined pricing, favorable product mix, and improved operating leverage

3. India delivered strong mid-teens volume growth across both Performance Surfactants and Specialty Care segments

4. AMET delivered strong mid-teens volume growth both YoY and QoQ

5. ROW volumes declined high single digits primarily due to supply-chain disruptions impacting APAC and Europe

6. Raw material markets remained volatile with fatty alcohol prices elevated at average $2,763/MT in Q2FY27 ($2,806/MT in Q1FY27; $2,800/MT in Q2FY26)

7. Board approved interim dividend of ₹18 per share

Consolidated Balance Sheet (as of September 30, 2026)

  • Total Assets: ₹4,471.7 Cr vs ₹3,874.2 Cr as of March 31, 2026
  • Total Shareholders' Fund: ₹2,970.8 Cr vs ₹2,744.8 Cr as of March 31, 2026
  • Inventories: ₹1,024.2 Cr vs ₹793.7 Cr as of March 31, 2026
  • Trade Receivables: ₹1,113.4 Cr vs ₹750.4 Cr as of March 31, 2026
  • Cash and Cash Equivalents: ₹265.5 Cr vs ₹109.1 Cr as of March 31, 2026
  • Total Current Liabilities: ₹1,352.0 Cr vs ₹1,016.4 Cr as of March 31, 2026

Consolidated Cash Flow Statement (H1FY27)

  • Net cash flows from Operating Activities: ₹76.6 Cr
  • Net cash flows from Investing Activities: ₹116.1 Cr
  • Net cash flows from Financing Activities: -₹37.6 Cr
  • Net increase in cash and cash equivalents: ₹155.1 Cr
  • Closing cash and cash equivalents: ₹265.5 Cr

Standalone Performance

Q2FY27 Standalone

  • Net Revenue from Operations: ₹1,233.2 Cr, up 34.2% YoY
  • EBITDA: ₹121.3 Cr, up 46.2% YoY
  • PAT: ₹66.5 Cr, up 43.9% YoY
  • EPS: ₹18.76

H1FY27 Standalone

  • Net Revenue from Operations: ₹2,498.8 Cr, up 39.4% YoY
  • EBITDA: ₹295.0 Cr, up 78.6% YoY
  • PAT: ₹172.4 Cr, up 95.4% YoY
  • EPS: ₹48.64

Management Commentary

Mr. K. Natarajan, Managing Director, commented on the strong performance citing broad-based growth in India, continued recovery in AMET, and sustained momentum in Specialty Care. He highlighted disciplined commercial decisions and diversified portfolio as key enablers of robust performance despite challenging external environment. The company remains vigilant regarding developments in West Asia and their potential implications for global logistics, freight rates, and feedstock availability.

Company Overview

  • Serving 1,500+ clients across 95+ countries
  • 2,000+ employees across all facilities